NDA 210598 · Mylan Ireland LTD
Yupelri
Revefenacin · Inhalation · Anticholinergic
NovelLast checked: Nov 19, 2026Latest source record: May 25, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Nov 9, 2018
Approved uses
1
Original approval plus efficacy supplements
Registered trials
20
6 Phase 3, 1 recruiting
FAERS reports
921
519 serious, 77 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 3, 2022.
YUPELRI is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is an anticholinergic indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD) .
Mechanism: Revefenacin is a long-acting muscarinic antagonist, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of M3 receptor at the smooth muscle leading to bronchodilation. The competitive and reversible nature of antagonism was shown with human and animal origin receptors and isolated organ preparations. In preclinical in vitro as well as in vivo models, prevention of methacholine- and acetylcholine-induced bronchoconstrictive effects was dose-dependent...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- YUPELRI · REVEFENACIN 175MCG/3ML · SOLUTION, INHALATION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Revefenacin" as an intervention, any sponsor and status, largest first.
- A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingCompleted
Mylan Inc.Industry
NCT02518139 · 1,060 participants · Start Sep 2015 · Primary completion Jun 2017
Drug: TD-4208; Tiotropium · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Easley, South Carolina
- Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingCompleted
Mylan Inc.Industry
NCT02459080 · 619 participants · Start Sep 2015 · Primary completion Aug 2016
Drug: TD-4208; Placebo · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Portland, Oregon
- Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingCompleted
Mylan Inc.Industry
NCT02512510 · 611 participants · Start Sep 2015 · Primary completion Aug 2016
Drug: TD-4208; Placebo · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Easley, South Carolina
- Phase 4 COPD and Suboptimal Inspiratory Flow RatePivotal-lookingCompleted
Theravance BiopharmaIndustry
NCT05165485 · 404 participants · Start Jan 7, 2022 · Primary completion Nov 13, 2023
Drug: Revefenacin; Tiotropium and 2 more · For: Chronic Obstructive Pulmonary Disease
Sites: Jasper, Alabama; Phoenix, Arizona; Tucson, Arizona · 76 sites in all
- A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingCompleted
Mylan Inc.Industry
NCT02040792 · 355 participants · Start May 2014 · Primary completion Jul 2014
Drug: TD-4208; Placebo · For: COPD
Sites: Greenville, South Carolina
- Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD)Pivotal-lookingNot yet recruiting
University of Tennessee Graduate School of MedicineAcademic, hospital or other
NCT07721922 · 280 participants (planned) · Start Nov 12, 2026 · Primary completion Sep 1, 2028
Drug: Revefenacin; formoterol fumarate and 2 more · For: COPD Exacerbation
Sites: Knoxville, Tennessee
- Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)Pivotal-lookingCompleted
Mylan Pharma UK Ltd.Industry
NCT05046795 · 258 participants · Start Nov 10, 2021 · Primary completion Jul 26, 2023
Drug: Revefenacin 175 mcg in 3 ML Inhalation Solution; Placebo inhalation solution QD · For: COPD
Sites: Hefei, China; Beijing, China; Guangzhou, China · 35 sites in all
- Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPDPivotal-lookingCompleted
Mylan Inc.Industry
NCT03095456 · 207 participants · Start Mar 27, 2017 · Primary completion Nov 25, 2017
Drug: Revefenacin; Placebo for Revefenacin and 1 more · For: Chronic Obstructive Pulmonary Disease, COPD; Low Peak Inspiratory Flow Rate (PIFR)
Sites: Rock Hill, South Carolina
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea240
- cough68
- headache60
- fatigue58
- death50
- pneumonia49
- chronic obstructive pulmonary disease48
- drug ineffective47
- nausea47
- dizziness43
- off label use41
- diarrhoea40
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2019 | 78 |
| 2020 | 92 |
| 2021 | 81 |
| 2022 | 60 |
| 2023 | 109 |
| 2024 | 80 |
| 2025 | 191 |
| 2026 | 229 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Yupelri (Revefenacin)
2024 spending
$7.2M
Beneficiaries
1,636
5,673 claims
Per beneficiary
$4,418
$16.81 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,351,014 |
| 2021 | $1,567,644 |
| 2022 | $2,154,000 |
| 2023 | $4,401,830 |
| 2024 | $7,228,259 |
Part B: Yupelri (Revefenacin) · HCPCS J7677
2024 spending
$175M
Beneficiaries
29,240
175,788 claims
Per beneficiary
$5,987
2024 ASP limit $0.19 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $123,252,921 |
| 2021 | $138,164,555 |
| 2022 | $155,971,190 |
| 2023 | $172,733,427 |
| 2024 | $175,048,323 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Revefenacin Area Under the Curve Spirometry in Patients with Moderate to Very Severe COPD.
LeMaster WB, Witenko CJ, Lacy MK, et al. · Int J Chron Obstruct Pulmon Dis 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Improvements in health status with revefenacin, a once-daily, nebulized, long-acting muscarinic antagonist for chronic obstructive pulmonary disease.
Donohue JF, Ferguson GT, Ohar JA, et al. · Respir Med 2023 · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
- Revefenacin Absorption, Metabolism, and Excretion in Healthy Subjects and Pharmacological Activity of Its Major Metabolite.
Bourdet DL, Yeola S, Hegde SS, et al. · Drug Metab Dispos 2020 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Maintained therapeutic effect of revefenacin over 52ߙweeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD).
Donohue JF, Kerwin E, Sethi S, et al. · Respir Res 2019 · Clinical Trial, Phase III, Randomized Controlled Trial
- Safety evaluation of revefenacin at the approved dose in patients with chronic obstructive pulmonary disease: A meta-analysis.
Liu B, Zan S, Luo W · Heart Lung 2022 · Meta-Analysis
- Revefenacin, a Long-Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo- and Positive-Controlled Thorough QT Study.
Borin MT, Barnes CN, Darpo B, et al. · Clin Pharmacol Drug Dev 2020 · Clinical Trial, Phase I, Randomized Controlled Trial
Sponsor: Mylan Ireland LTD
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.